[Non-myeloablative allogeneic stem cell transplantation].

Abstract

BACKGROUND:

Several haematological malignancies can be cured using allogeneic stem cell transplantation (SCT). Maximal tolerable chemoradiotherapy doses are given as part of the conditioning-regimen. This treatment causes substantial toxicity, and the procedure is therefore restricted to patients younger than 60 years without co-morbidity. Non-myeloablative allogeneic SCT, is a treatment modality that can be offered to patients up to 70 years of age and to younger patients with co-morbidity.

MATERIAL AND METHODS:

21 patients (17 men and 4 women) with different haematological malignancies, have been treated with non-myeloablative allogeneic SCT in our institution from October 2000 to May 2005.

RESULTS:

The transplant procedure was relatively non-toxic. Four patients required transfusions and 3 required empirical antibiotic treatment, which is always necessary after myoablavative allogen SCT. A stable donor chimerism was achieved for most of our patients before day 84. 11 patients suffered from acute graft versus host disease (GVHD), 6 with debut of symptoms after day 100. 11 patients developed chronic GVHD. 14 patients are alive and 7 are dead; 2 due to transplant-related complications and 5 due to disease progression.

INTERPRETATION:

We have shown that non-myeloablative allogeneic SCT is feasible with an acceptable toxicity. Acute and chronic GVHD is still a substantial problem. Prospective studies with adequate controls are warranted to determine the future role of non-myeloablative allogeneic SCT.

• Authors: Jakob Dalgaard, Yngvar Fløisand, Margurethe Stenersen, Torstein Egeland, Lorentz Brinch
• Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (Tidsskr Nor Laegeforen) Vol. 127 Issue 6 Pg. 721-4 (Mar 15 2007) ISSN: 0807-7096 [Electronic] Norway
• Vernacular Title: Allogen stamcelletransplantasjon med redusert forbehandling.
• PMID: 17363982 (Publication Type: English Abstract, Journal Article)

Topics

• Adult
• Female
• Graft vs Host Disease (etiology, immunology, prevention & control)
• Hematopoietic Stem Cell Transplantation (adverse effects, methods)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (therapy)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
• Leukemia, Myeloid, Acute (therapy)
• Male
• Middle Aged
• Remission Induction
• Transplantation Conditioning (methods)
• Transplantation, Autologous
• Transplantation, Homologous
• Treatment Outcome